XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Other current assets | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from counterparty $ 105   $ 105   $ 52
Other current assets | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from counterparty 98   98   71
Other current assets | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from counterparty 41   41   32
Accounts payable and accrued liabilities | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to counterparty 605   605   405
Accounts payable and accrued liabilities | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to counterparty 709   709   375
Other Noncurrent Liabilities | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to counterparty 300   300   250
Other Noncurrent Liabilities | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to counterparty 125   125   543
Other Noncurrent Liabilities | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to counterparty 375   375   $ 375
Revenue | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total sales 111 $ 44 190 $ 76  
Revenue | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total sales 97 35 171 35  
Revenue | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net product sales recorded by Merck 53 47 100 90  
Merck’s profit share from sales in Bayer’s marketing territories 51 28 94 53  
Total sales 104 75 194 143  
Cost of sales | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 73 24 92 36  
Cost of sales | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 23 1 74 1  
Cost of sales | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 29 132 58 159  
Selling, general and administrative | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 33 9 59 16  
Selling, general and administrative | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 19 2 38 2  
Selling, general and administrative | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 11 10 20 17  
Research and development | AstraZeneca          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 33 42 78 71  
Research and development | Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses 62 36 109 1,436  
Research and development | Bayer AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Expenses $ 32 $ 28 $ 62 $ 56